NH BAE

the next generation of antibody–drug conjugates will require more than better payloads. a new review examines how antibody targeting, linker chemistry, drug loading, and tissue exposure collectively determine adc toxicity. improving the therapeutic window requires optimizing the entire molecular system. doi.org/10.1038/s41392-026-0…

what if we could degrade gpcrs instead of simply inhibiting them? a nature study describes a bifunctional antibody-based platform that rewires receptor trafficking to drive gpcr degradation and antagonism. an interesting expansion of targeted protein degradation beyond intracellular proteins. doi.org/10.1038/s41586-026-1…

covalent drug discovery is moving beyond cysteine. new work in ACS chemical biology reports JL-03, a lys162-targeting eIF4E inhibitor using a vinyl acylsulfonamide electrophile. the interesting chemistry: the protein binding site helps activate the electrophile, enabling selective lysine modification. a compelling example of exploiting local protein microenvironments for covalent drug discovery. lifescience.net/publications…